EMA Recommends Granting a Marketing Authorisation for Nirogacestat By Ogkologos - July 3, 2025 233 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adult patients with progressing desmoid tumours Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR Immune Checkpoint Inhibitor Induced Thyroiditis Associated with a Large Reduction in... May 20, 2021 Inspired By Her Mom’s Breast Cancer Battle, Girl Sells ‘Cancer Bears’... March 11, 2021 Stopping Treatment Is a Reasonable Strategy for Patients with Advanced NSCLC... June 30, 2023 KRASG12 Mutations Are Biomarkers for Reduced Overall Survival Benefit of Treatment... March 14, 2023 Load more HOT NEWS How My Cancer Diagnosis Has Fueled My Work in Improving Access... Program Helps Medically Underserved, Minority Cancer Survivors Be More Active The art of practicing sustainable science Neoadjuvant Nivolumab/Relatlimab Induces High Rates of Pathologic Responses in Patients with...
